Azone enhances clinical effectiveness of an optimized formulation of triamcinolone acetonide in atopic dermatitis.
Int J Dermatol
; 40(3): 232-6, 2001 Mar.
Article
em En
| MEDLINE
| ID: mdl-11422533
ABSTRACT
BACKGROUND:
Atopic dermatitis is a chronic, relapsing condition affecting up to 14% of the population in Western countries. Topical corticosteroids are the mainstay of treatment. Triamcinolone acetonide, a corticoid of intermediate potency, has proven useful in the treatment of atopic dermatitis.AIM:
To evaluate the effectiveness of a triamcinolone acetonide-laurocapram combination in the treatment of atopic dermatitis.METHODS:
One hundred and fifty patients were enrolled in a three-arm, parallel group, controlled clinical trial evaluating the effectiveness of a triamcinolone acetonide (0.05%) and laurocapram combination, applied twice daily for 2 weeks, in the treatment of atopic dermatitis. Fifty patients received triamcinolone acetonide-laurocapram (TNX), 50 triamcinolone acetonide (TN), and 50 a vehicle control formulation (AN). Response to treatment was evaluated by change in disease severity at 6 h, at 3, 8, and 15 days after the start of treatment, and by the global change in disease status.RESULTS:
TNX effected a significantly higher degree of improvement in the signs and symptoms of atopic dermatitis (erythema, induration, and pruritus) and a greater overall improvement in disease status compared with treatment with TN or AN. Treatment-associated side-effects were local reactions, occurring in three, two, and six patients in the TNX, TN, and AN groups, respectively.CONCLUSIONS:
The results suggest that the incorporation of laurocapram in the formulation enhances the effectiveness of triamcinolone acetonide, without compromising its safety profile.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Azepinas
/
Triancinolona Acetonida
/
Dermatite Atópica
/
Anti-Inflamatórios
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
Int J Dermatol
Ano de publicação:
2001
Tipo de documento:
Article
País de afiliação:
Estados Unidos